Publications

Detailed Information

Ramosetron for the prevention of cisplatin-induced acute emesis: A prospective randomized comparison with granisetron

Cited 31 time in Web of Science Cited 37 time in Scopus
Authors

Kang, YK; Park, YH; Ryoo, BY; Bang, YJ; Cho, KS; Shin, DB; Kim, HC; Lee, KH; Park, YS; Lee, KS; Heo, DS; Kim, SY; Cho, EK; Lim, HY; Kim, WK; Lee, JA; Kim, TY; Lee, JC; Yoon, HJ; Kim, NK

Issue Date
2002-05
Publisher
Cambridge Medical Publications
Citation
Journal of International Medical Research, Vol.30 No.3, pp.220-229
Abstract
Control of nausea and vomiting is very important in determining patient compliance with cisplatin chemotherapy. A multicentre, randomized, single-blind study was conducted to compare the tolerability and efficacy of ramosetron with those of granisetron over 24 h following cisplatin administration to cancer patients. In eight study centres, a total of 194 adult patients were randomly assigned to receive either intravenous ramosetron 0.3 mg or intravenous granisetron 3.0 mg. The anti-emetic effect of ramosetron determined from the no-vomiting rate lasted longer, but there was no significant difference in the number of acute vomiting episodes or the severity of nausea between the two groups. In the tolerability evaluation, there were no statistically significant differences between the two groups, except for a higher incidence of dull headache in the granisetron group. Ramosetron and granisetron appear to have equivalent efficacy and tolerability profiles, but the effects of ramosetron on the prevention of acute vomiting in patients undergoing cisplatin chemotherapy were longer lasting.
ISSN
0300-0605
URI
https://hdl.handle.net/10371/173158
DOI
https://doi.org/10.1177/147323000203000302
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share